市場調查報告書
商品編碼
1467696
2024-2032 年按產品、系統類型、應用、最終用戶(醫院、學術和政府研究機構、製藥和生物技術公司、合約研究組織)和地區分類的雷射捕獲顯微切割市場報告Laser Capture Microdissection Market Report by Product, System Type, Application, End User (Hospitals, Academic and Government Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations ), and Region 2024-2032 |
IMARC Group年,全球雷射捕獲顯微切割市場規模達到 1.483 億美元。
雷射捕獲顯微切割 (LCM) 是一種使用雷射光束和直接顯微可視化將細胞與其周圍組織分離的高解析度方法。它依靠紫外線 (UV)、紅外線和免疫螢光雷射光束從組織、血液和精液樣本中收穫純淨的富集細胞群。它可以準確區分正常細胞和異常細胞以研究亞細胞概況。它用於福馬林固定、石蠟包埋、冷凍和細胞學標本,用於研究基因表現和檢測癌症。此外,它還應用於學術和政府研究機構、製藥和生物技術公司、聚合酶鍊式反應 (PCR)、蛋白質組學以及醫院的下一代和桑格測序。
生物科學研究實驗室中分子分析的使用不斷增加,以及醫療保健產業的不斷擴大,是推動市場的關鍵因素之一。此外,由於LCM可以透過靈敏的分析技術對細胞群(例如霍奇金氏病和原位癌的惡性細胞)進行精確的體內檢查,因此其在全球的銷售量正在不斷成長。此外,一些國家政府的醫療保健支出和研發 (R&D) 資金也有所增加。再加上法醫科學和分子生物學中心對 LCM 以獲得可解釋的 DNA 圖譜的需求不斷成長,正在刺激市場成長。除此之外,LCM也用於建立特定病理病變和惡性腫瘤的遺傳指紋,以識別新的診斷和預後標記。它還有助於提供腫瘤的個人化治療,這對市場產生了積極影響。此外,主要市場參與者正在引入配備免疫螢光雷射二極體的增強型 LCM 技術,以改善生物標記發現和癌症化學預防,預計這將促進市場的成長。
The global laser capture microdissection market size reached US$ 148.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 329.3 Million by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032.
Laser capture microdissection (LCM) is a high-resolution method of isolating cells from their surrounding tissues using a laser beam and direct microscopic visualization. It relies on ultraviolet (UV), infrared, and immunofluorescence laser beams to harvest pure enriched cell populations from tissue, blood, and semen samples. It accurately differentiates between normal and abnormal cells to investigate subcellular profiles. It is used on formalin-fixed, paraffin wax-embedded, frozen, and cytologic specimens for studying gene expression and detecting cancer. In addition, it finds application in academic and government research institutes, pharmaceutical and biotechnology companies, polymerase chain reaction (PCR), proteomics, and hospitals for next-generation and sanger sequencing.
The growing utilization of molecular analysis in a bioscience research laboratory, along with the expanding healthcare industry, represents one of the key factors driving the market. Moreover, as LCM allows precise vivo examination of cell populations, such as malignant cells of Hodgkin's disease and carcinoma in situ with sensitive analytical techniques, its sales are rising across the globe. Additionally, there is an increase in healthcare expenditure and research and development (R&D) funding by governments of several countries. This, along with the escalating demand for LCM in forensic science and molecular biology centers to obtain interpretable DNA profiles, is stimulating the market growth. Besides this, LCM is utilized for establishing genetic fingerprints of specific pathological lesions and malignant neoplasms to identify new diagnostic and prognostic markers. It also helps provide individualized treatment of tumor, which is positively influencing the market. Furthermore, key market players are introducing enhanced LCM technologies equipped with immunofluorescence laser diodes for improved biomarker discovery and cancer chemoprevention, which is projected to bolster the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global laser capture microdissection market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, system type, application and end user.
Instruments
Consumables
Software and Services
Ultraviolet LCM
Infrared LCM
Others
Research and Development
Diagnostics
Others
Hospitals
Academic and Government Research Institutes
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROs)
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AnaPath Services GmbH (ST Pharm Co. Ltd), Bio-RAD Laboratories Inc., Caresbio Laboratory LLC, Carl Zeiss Meditec AG (Carl Zeiss AG), Epistem Ltd, Fluidigm Corporation, Gnome Diagnostics LLC, HUBNER Photonics, Leica Microsystems GmbH (Danaher Corporation), Molecular Machines & Industries, Thermo Fisher Scientific Inc. and VitroVivo Biotech.